NCT02836613View on ClinicalTrials.gov

A Study of Galcanezumab in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

February 27, 2017

Study Completion Date

November 9, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

Galcanezumab

Administered SC

Trial Locations (3)

32117

Covance Clinical Research Inc, Daytona Beach

47710

Covance Clinical Research Inc, Evansville

75247

Covance, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02836613 - A Study of Galcanezumab in Healthy Participants. | Biotech Hunter | Biotech Hunter